⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

Official Title: Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study

Study ID: NCT02223208

Study Description

Brief Summary: This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study. 2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.

Detailed Description: PHASE I A1) Induction phase Ro-CHOEP-21 x 3 cycles * Romidepsin (dose escalation) starting dose: 12mg/ms iv day +1 and +8. Dose modification according to toxicity (14mg/ms day +1 and +8; 10mg/ms day +1 and +8; 8mg/ms day +1 and +8); * CHOEP-21 (Doxorubicin 50 mg/ms iv day +1; Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1; Cyclophosphamide 750 mg/ms iv day +1; Etoposide 100mg/ms iv from day +1 to +3; Prednisone100 mg orally from days +1 to +5). According to the response achieved after the first 3 Ro-CHOEP-21 cycles: * PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by phase A2 * SD or PD: Treatment failures, proceed to salvage according to each institutional policy. A2) Stem cell mobilization and transplantation phase Response evaluation and one DHAP course followed by peripheral stem cell harvesting. According to response achieved after 6 Ro-CHOEP-21 cycles: CR: BEAM or FEAM or CEAM followed by auto-SCT PR * Allogeneic SCT with HLA-identical (A, B, C, DR, DQ loci) or one antigen mismatched (class I) sibling donors. Donor selection is based on molecular high-resolution typing (4 digits) of the HLA gene loci class I (HLA-A, B, and C) and class II (DRB1, DQB1). In case, no class I and class II completely identical urelated donor (10 out of 10 gene loci) can be identified, the degree of histocompatibility between patient and donor must fulfill with the minimal degree of matching established by the Italian Bone Marrow Donor Registry: HLA-A and HLA-B antigen histocompatibility and HLA-DRB1 allelic histocompatibility. * when a suitable donor is not available: BEAM or FEAM or CEAM followed by Auto-SCT. * Haploidentical transplantation is allowed in selected cases \< PR: Treatment failures, proceed to salvage according to each institutional policy. PHASE II A1) Induction phase Ro-CHOEP-21 x 3 cycles * Romidepsin dose according to phase I iv day +1 and +8 * Doxorubicin 50 mg/ms iv day +1, * Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1, * Cyclophosphamide 750 mg/ms iv day +1, * Etoposide 100mg/ms iv from day +1 to +3 * Prednisone100 mg orally from days +1 to +5 According to the response achieved after the first 3 Ro-CHOEP-21 cycles: * PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by phase A2 * SD or PD: Treatment failures, proceed to salvage according to each institutional policy. A2) Stem cell mobilization and transplantation phase Response evaluation and one DHAP course followed by peripheral stem cell harvesting. According to response achieved after 6 Ro-CHOEP-21 cycles: CR: BEAM or FEAM or CEAM followed by auto-SCT PR * Allogeneic SCT with HLA-identical (A, B, C, DR, DQ loci) or one antigen mismatched (class I) sibling donors. Donor selection is based on molecular high-resolution typing (4 digits) of the HLA gene loci class I (HLA-A, B, and C) and class II (DRB1, DQB1). In case, no class I and class II completely identical urelated donor (10 out of 10 gene loci) can be identified, the degree of histocompatibility between patient and donor must fulfill with the minimal degree of matching established by the Italian Bone Marrow Donor Registry: HLA-A and HLA-B antigen histocompatibility and HLA-DRB1 allelic histocompatibility. * when a suitable donor is not available: BEAM or FEAM or CEAM followed by Auto-SCT. * Haploidentical transplantation is allowed in selected cases \< PR: Treatment failures, proceed to salvage according to each institutional policy.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy

Policlinico S. Orsola Malpighi, Bologna, BO, Italy

Spedali Civili, Brescia, BS, Italy

Ospedale Businco, Cagliari, CA, Italy

Azienda Ospedaliera S.Croce e Carle, Cuneo, CN, Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Sede di Meldola, Meldola, FC, Italy

IRCCS AOU San Martino - Clinica Ematologica, Genova, GE, Italy

IRCCS AOU San Martino - UO Ematologia 1, Genova, GE, Italy

Istituto Clinico Humanitas, Rozzano, Milano, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, MI, Italy

Fondazione IRCCS "Istituto Nazionale dei Tumori", Milano, MI, Italy

Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milano, MI, Italy

AO Ospedali Riuniti Villa Sofia - Cervello (Presidio Cervello), Palermo, PA, Italy

IRCCS Centro di Riferimento Oncologico (CRO), Aviano, PN, Italy

AOU di Parma, Parma, PR, Italy

Fondazione IRCCS - Policlinico San Matteo, Pavia, PV, Italy

IRCCS Arcispedale "Santa Maria Nuova", Reggio Emilia, RE, Italy

Ospedale degli Infermi, Rimini, RN, Italy

AO Città della Salute e della Scienza - Ematologia 1U, Torino, TO, Italy

AO Città della Salute e della Scienza - SC Ematologia, Torino, TO, Italy

AOU "Santa Maria della Misericordia", Udine, UD, Italy

Ospedale Borgo Roma, Verona, VR, Italy

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, , Italy

Ospedale Maggiore della Carità - SCDU Ematologia, Novara, , Italy

A.O. di Perugia - Santa Maria della Misericordia, Perugia, , Italy

Ospedale G. Da Saliceto - AUSL di Piacenza, Piacenza, , Italy

UO Ematologia Ospedale S.Maria delle Croci, Ravenna, , Italy

Contact Details

Name: Paolo Corradini, Prof

Affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: